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Thrombotic thrombocytopenic purpura (TTP) is an uncommon life-threatening disease characterized by microangiopathic
hemolyticanemiaandthrombocytopenia,commonlyassociatedwithinfections,malignancy,drugs,andautoimmunediseases.We
reportacaseof19-year-oldpreviouslyhealthyfemalethatpresentswithanemiaandthrombocytopeniadiagnosedwiththrombotic
thrombocytopenicpurpura thatwastreatedsuccessfullywithplasmapheresisandcorticosteroids.Laboratoryﬁndingsalsorevealed
antinuclear antibodies and antibodies to double-stranded DNA. Two weeks after presentation developed inﬂammatory arthritis,
fulﬁlling diagnostic criteria for systemic lupus erythematosus (SLE). Prompt diagnosis and treatment with plasma exchange and
corticosteroids should be instituted as soon as the diagnosis of TTP is suspected, even if other diagnoses, including lupus, are
possible.Whenpresent, the coexistence of these twoetiologies canhavea highermortality thaneitherdisease alone.An underlying
diagnosis of SLE should be considered in all patients presenting TTP and the study of this association may provide a better
understanding of their immune-mediated pathophysiology.
1.Background
The relation between the systemic lupuserythematous(SLE)
and thrombotic microangiopathies, including malignant
hypertension, antiphospholipid syndrome, and thrombotic
thrombocytopenic purpura (TTP) has always presented
several diagnostic diﬃculties. TTP, an uncommon life-
threatening disease, can present in approximately 2% of the
patients with SLE [1]. However, this occurs commonly in
patients with active SLE disease. TTP as the initial manifes-
tation of SLE is not only an extremely uncommon scenario,
but also one with potentially high mortality [1]. Therefore,
the presentation of a patient with TTP rarely prompts
clinicians to work up for secondary autoimmune diseases,
includingSLE.Herein, we review thepathophysiology ofthis
relationshipandpossiblenewtherapeuticapproachesforthis
uncommon clinical scenario.
2.CasePresentation
A previously healthy 19-year-old African American female
presented to the emergency room complaining of a 2-day
history of generalized fatigue, bruising over the upper and
lower extremities as well as headaches, but no signs of
bleeding from oriﬁces. She did not have any signiﬁcant past
medical history or surgical history. Other than medroxypro-
gesterone acetate injections for contraception and ibuprofen
for infrequent migraine, she was not taking any medications.
Her menstrual periods were regular and predictable and
she denied any prior pregnancy or abortion. The review
of systems was only positive for recent increased hair loss,
but otherwise negative. On physical examination she had
temperature of 99.1 degree Fahrenheit, pulse was rapid and
regular at 116beats/min, blood pressure of 120/75mmHg,
respiration at 16 per minute. She was fully alert and
oriented, but with pale skin and with bruising on upper and
lower extremities. Cardiovascular examination revealed only
tachycardia but no added sounds, and her abdomen was soft
without tenderness or hepatosplenomegaly on palpation.
The rest of the physical examination was unremarkable. The
initial laboratory workup revealed hemoglobin of 6.1g/dL,
normal MCV, a high reticulocyte index of 4%, thrombo-
cytopenia of 9,000 × 10−6/L and normal white blood cell2 Case Reports in Medicine
count. Peripheral blood smear revealed 5 schistocytes per
hpf, anisocytosis, poikilocytosis, and some tear drop cells as
well. The coagulation proﬁle was within the normal limits.
The LDH was 1624IU/L, AST of 90IU/L, ALT of 78IU/L,
and total bilirubin was 1.9mg/dL with direct bilirubin of
0.4. Direct Coombs’ test was negative, and haptoglobin
level was normal, attributed to the inﬂammatory process
that was later revealed. Renal function was preserved with
a creatinine of 0.7mg/dL, and all the serum electrolytes
were within the normal range. Urine pregnancy test was
negative. Urinalysis revealed proteinuria of 30mg/dL. She
was admitted to the Intensive Care Unit, and treatment was
started with methylprednisolone 1 gram intravenously daily
for 3 days with a decreased dose thereafter, in conjunction
with two daily sessions of plasmapharesis. She improved
remarkably, with a normalization of her platelet count in 10
days, and her liver enzymes, LDH, and hemoglobin all were
corrected within 2 weeks (Figure 1).
She also had a positive antinuclear antibody (ANA)
screening with speckled pattern and titer of 1:640; antidou-
ble stranded DNA (dsDNA) antibodies level was elevated
at 36.37IU/L. Other serologies including lupus anticoagu-
lant, anti-B2-glycoprotein, anticardiolipin, antismith, anti-
RNP, C3, and C4 complements levels were all negative.
Interestingly, the patient was found to have ADAMTS13
activity below 5% and inhibitor to ADAMTS13 with a
level of 0.8UmL−1. One week after ﬁnishing the course
of plasmapheresis, and after steroids were discontinued,
she developed tenderness and swelling of both ankles,
fulﬁlling criteria for SLE diagnosis (hemolytic anemia and
thrombocytopenia, inﬂammatory arthritis, positive ANA
and positive dsDNA). Other diagnostic criteria as malar or
discoid rash, photosensitivity, oral ulcers, serositis, renal, or
neurologic ﬁndings were not seen.
3.Discussion
The early recognition of TTP in this patient and the prompt
workup of her associated underlying disease allowed an early
eﬀective treatment and followup, improving not only the
immediate outcome, but also her long-term prognosis.
After the initial description of TTP by Moschowitz in
1924, a pentad of severe thrombocytopenia, microangio-
pathic hemolytic anemia, neurologic abnormalities, renal
insuﬃciency, and fever was established in 1966 by Amorosi
and Ultmann [2, 3]. Since then, the mortality of TTP has
decreased dramatically from 90% without treatment to 8–
25% with the institution of plasma exchange transfusion [4].
This resulted in the diagnostic criteria to be revised from
the earlier pentad to the current dyad of thrombocytopenia
and microangiopathic hemolytic anemia, with no clinically
apparent alternative explanation for thrombocytopenia and
anemia[3,5–7].Duringthelastdecade,themainpathophys-
iologicfeatureofTTP has beendescribedasseveredeﬁciency
of von Willebrand Factor (vWF) cleaving metalloproteinase
(ADAMTS-13), which normally cleaves the unusually large
vWF into smaller and less adhesive vWF moeity. This deﬁ-
ciency is thought to be possibly secondary to the presence of
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Figure 1: Platelets and LDH logarithmic trend in hospital.
an IgG antibody inhibiting ADAMTS-13 activity, inhibition
that ﬁnally allows the presence of units of unusually large
vWF which is responsible for the microvascular thrombosis,
hemolysis, and thrombocytopenia [3, 8].
Connective tissue disorders, including SLE, can present
with low levels of ADAMTS-13, suggesting a possible
common pathophysiology for these diseases [9]. TTP occur-
ring in patients with SLE can be diﬃcult to diagnose
because of overlapping features of the two disorders and
the presence of other potentially concomitant thrombotic
microangiopathies [9]. When developed in patients with
SLE, TTP usually presents in patients previously diagnosed
and treated for SLE for several years, with a high SLE disease
activity index score and coexisting nephritis, having a higher
mortality thaneitherdisease alone[1,9].Theclinicaloverlap
between these two syndromes has been described more
commonly in young black women, as the case described
[10]. Also, this concomitant scenario has been described
to have a “slower tempo” of development, possible because
patients diagnosed with SLE were already being treated
with immunosuppressive therapy and corticosteroids, a fact
that may suppress the immune mechanisms involve in
TTP development. However, the delay in establishing the
diagnosis of TTP in a patient with SLE might also bias this
“slow tempo” of development [11].
The inverse sequence of events observed in our case trig-
gers the questionof how useful it would be to screen patients
that present with suspected TTP with ANA. Although SLE
may present with hemolytic anemia, thrombocytopenia,
neurologic deﬁcits, fever, and renal insuﬃciency, the ﬁnding
of fragmented RBCs or schistocytes favors the diagnosis of
TTP [12]. An initial schistocyte count of more than 1%
in the absence of any other cause for thrombocytopenia is
strongly suggestive of TTP. Although the American College
of Rheumatology classiﬁcation criteria for SLE are >90Case Reports in Medicine 3
percent speciﬁc and sensitive, the clinical presentation of
isolated TTP may be indistinguishable from that of SLE
with secondary TTP during the acute initial episode of
TTP [13]. The underlying reason for the association of SLE
with TTP is unknown. There is still considerable debate
about whether certain antiphospholipid antibodies or lupus
anticoagulantplayapathogenicroleintriggeringTTP inSLE
patients, although neither of these two types of antibodies
has to be present for SLE patients to develop TTP [14]. The
relationshipbetweentheADAMTS-13inhibitorandSLEalso
needs to be further investigated, since its presence in patients
with SLE and concomitant TTP had not been described
in the few small retrospective series available because the
test was not available at that time. Mortality rate of TTP
in patients with SLE has been reported to be 46–50% in
two small series, and was associated with the presence of
concomitant infections and the delay in the initiation of
plasma exchange therapy [1, 9].
Plasma exchange continues to be the mainstay of
treatment in patients with TTP, even when concomitant
SLE is present. Other therapies that have been used with
variable results include high-dose steroids, cytotoxic agents
such as cyclophosphamide and vincristine, and intravenous
immunoglobulin.Rituximab,amonoclonalantibodyagainst
CD20 receptor, has been used in four reported cases of
refractory TTP in SLE patients, with a response and disease-
speciﬁc survival of 50% [11, 15, 16].
The association of SLE and TTP is uncommon, but
potentially lethal, even with current treatment strategies,
emphasizingtheimportanceofearlydiagnosisandaggressive
management with plasma exchange and immunosuppres-
sion. In refractory cases, the use of rituximab may be an
option, although currently its use is limited to a few cases.
If diagnosis of either disease is present, the possibility of the
other needs to be considered if clinically suggested, since
the prognosis and treatment can vary. Critical care spe-
cialists, rheumatologists, and hematologists need to evolve
an urgent multidisciplinary approach which emphasizes the
early recognition of this phenomenon and the initiation of
early treatment which secure a better outcome.
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